Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release.
The acquisition includes the 1% and 0.5% formulations of Iopidine (apraclonidine hydrochloride), Maxitrol 0.1% (neomycin and polymyxin B sulfate and dexamethasone) and Moxeza 0.5% (moxifloxacin hydrochloride).
The company plans to sell, market and distribute the products through subsidiary, ImprimisRx. Novartis will retain commercial rights outside of the U.S.
“These acquisitions, along with previously announced transactions for AMP-100, MAQ-100, and the